Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03006172
Title To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications

breast cancer

Advanced Solid Tumor

Therapies

GDC-0077 + Letrozole + Palbociclib

GDC-0077

Fulvestrant + GDC-0077

GDC-0077 + Letrozole

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | CAN

Additional content available in CKB BOOST